Image_3_Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment.jpeg
This meta-analysis aimed to better elucidate the predictive value of human epidermal growth factor receptor 2 (HER2)-enriched subtype of pathological complete response (pCR) rate within HER2-positive breast cancer patients receiving neoadjuvant treatment.
MethodsWe identified prospective trials that evaluated the correlation between an HER2-enriched subtype and pCR rate in HER2-positive breast cancer. Pooled odds ratio (OR) values with 95% confidence intervals (CIs) were computed.
ResultsFifteen studies comprising 2,190 patients met the inclusion criteria. The HER2-enriched subtype was associated with increased odds of achieving a pCR (OR = 4.12, 95% CI = 3.38 to 5.03, P < 0.001) in patients overall. Moreover, it was correlated with improved pCR when single or dual HER2-targeted agent-based therapy was employed (OR = 3.36, 95% CI = 2.25 to 5.02, P < 0.001; OR = 4.66, 95% CI = 3.56 to 6.10, P < 0.001, respectively), but not when HER2-targeted agent-free chemotherapy was used (OR = 2.52, 95% CI = 0.98 to 6.49, P = 0.05). Moreover, an HER2-enriched subtype predicted higher pCR rates irrespective of HER2-targeted agents (trastuzumab, lapatinib, pertuzumab, or T-DM1); chemotherapy agents (taxane-based, or anthracyclines plus taxane-based); endocrine therapy and hormone receptor [all the differences were statistically significant (P all ≤ 0.001)].
ConclusionsThe HER2-enriched subtype can more effectively and specifically predict pCR for HER2-targeted agent-based neoadjuvant treatment, irrespective of the number (single or dual) or category of HER2-targeted agent, including chemotherapy and endocrine therapy, or hormone receptor in cases of HER2-positive breast cancer.
History
References
- https://doi.org//10.1016/S0140-6736%2816%2931891-8
- https://doi.org//10.1038/nature11412
- https://doi.org//10.1093/annonc/mdu118
- https://doi.org//10.2174/1574887112666170202165049
- https://doi.org//10.1001/jamaoncol.2015.6113
- https://doi.org//10.1016/S0140-6736%2811%2961847-3
- https://doi.org//10.1016/S1470-2045%2813%2970411-X
- https://doi.org//10.1200/JCO.2015.62.1268
- https://doi.org//10.1155/2017/7849108
- https://doi.org//10.1001/jamaoncol.2016.3824
- https://doi.org//10.1158/1078-0432.CCR-13-0239
- https://doi.org//10.1093/annonc/mdw262
- https://doi.org//10.18632/oncotarget.20629
- https://doi.org//10.1200/JCO.2008.18.1370
- https://doi.org//10.1016/j.jcms.2010.11.001
- https://doi.org//10.1016/0197-2456%2886%2990046-2
- https://doi.org//10.1136/bmj.d5928
- https://doi.org//10.1136/bmj.315.7109.629
- https://doi.org//10.1093/annonc/mdx773
- https://doi.org//10.1093/annonc/mdx048
- https://doi.org//10.1016/S1470-2045%2817%2930021-9
- https://doi.org//10.1007/s10549-019-05398-3
- https://doi.org//10.1007/s12282-016-0677-4
- https://doi.org//10.1186/s12916-018-1233-1
- https://doi.org//10.1158/0008-5472
- https://doi.org//10.1093/jnci/djz042
- https://doi.org//10.1158/1538-7445
- https://doi.org//10.1158/1538-7445
- https://doi.org//10.1016/S1470-2045%2819%2930158-5
- https://doi.org//10.1056/NEJMoa1814017
- https://doi.org//10.1016/j.ctrv.2017.04.005
- https://doi.org//10.1200/JCO.2014.58.1967
- https://doi.org//10.1001/jamaoncol.2015.0830
- https://doi.org//10.1158/1078-0432.CCR-15-2338
- https://doi.org//10.1093/jnci/djy076
- https://doi.org//10.1200/JCO.2014.55.7876
- https://doi.org//10.1007/s10549-015-3480-6
- https://doi.org//10.1093/annonc/mdz076
- https://doi.org//10.1093/annonc/mdw197
- https://doi.org//10.1200/JCO.2013.54.7869
- https://doi.org//10.1016/j.ctrv.2020.101965
- https://doi.org//10.1185/03007995.2013.794775
- https://doi.org//10.1111/1759-7714.12618
- https://doi.org//10.1001/jamaoncol.2015.2286
- https://doi.org//10.1038/s41571-019-0268-3
- https://doi.org//10.1016/j.canlet.2014.05.019
- https://doi.org//10.1093/annonc/mdt287
CC BY 4.0